Global aptamers market is estimated to be valued at USD 7.29 Bn in 2024 and is expected to exhibit a CAGR of 17.8% during the forecast period (2024-2031). Aptamers are single stranded Deoxyribonucleic acid (DNA) or Ribonucleic acid (RNA) molecules that bind to a specific target molecule. These can be chemically synthesized to recognize and bind protein, small molecule or cell surface targets with high affinity and specificity. Aptamers have several advantages over antibodies such as small size, easy production and modification, lack of immunogenicity and better tissue penetration. These have wide applications in research, diagnostics, therapeutics and others.
Market Dynamics:
Global aptamers market growth is driven by rising research and development investments in life sciences and pharmaceutical industries. Growing use of aptamers as an alternative to antibodies in diagnostics and research due to their advantages is also boosting the market growth. However, high costs associated with aptamer development and production is a major factor hampering the market growth. Emergence of novel technologies for simpler and cost-effective production of aptamers provides a significant opportunity for market players.
Key Features of the Study:
- This report provides in-depth analysis of the global aptamers market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global aptamers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study AstraZeneca, Achiko AG, Agilent Technologies, Inc., Amsbio, Aptagen LLC, Aptamer Group, CAGE Bio Inc., GC Biopharma Corp., GlyTech, Inc., IVERIC bio, Inc., NeoNeuro SAS, Novartis AG, Ophthotech Corporation, SomaLogic Operating Co., Inc., TAGCyx Biotechnologies Inc., Vivonics Inc., Zentek Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global aptamers market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global aptamers market.
Detailed Segmentation-
- By Type:
- Nucleic Acid
- DNA-based Aptamers
- RNA-based Aptamers
- XNA-based Aptamers
- Peptide Aptamers
- By Application:
- Diagnostics
- Therapeutics
- Research and Development
- By End User:
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutions
- Contract Research Organization
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca
- Achiko AG
- Agilent Technologies, Inc.
- Amsbio
- Aptagen LLC,
- Aptamer Sciences, Inc.
- CAGE Bio Inc.
- GC Biopharma Corp.
- GlyTech, Inc.
- IVERIC bio, Inc.
- NeoNeuro SAS
- Novartis AG
- Ophthotech Corporation
- SomaLogic Operating Co., Inc.
- TAGCyx Biotechnologies Inc.
- Vivonics Inc.
- Zentek Ltd.
